Global Prostate Cancer Antigen 3 (PCA3) Test Market, By Type of Test (Instruments, Kits and Reagent and Consumables), Test Type (Molecular, Serology), Technology (RT-PCR, ELISA Test, Micro-neutralization Assays), End Use (Hospitals, Clinics, Public Health Labs, Private or Commercial Labs, Physician Labs, Research Institutes, Others) – Industry Trends and Forecast to 2029.
Prostate Cancer Antigen 3 (PCA3) Test Market Analysis and Size
The prostate cancer antigen 3 (PCA3) test looks for genetic material (messenger RNA (mRNA)) produced exclusively by the prostate. In normal prostate tissue, the protein PCA3 and its associated mRNA are present at low levels. PCA3 is found in high concentrations (overexpressed) in approximately 90% of prostate cancers. Prostate specific antigen (PSA) is also increased in prostate cancers, but it can also be increased in a variety of benign conditions. This test detects PCA3 mRNA and PSA mRNA in the first urine sample obtained after a digital rectal exam (DRE). The PCA3 score is reported by laboratories and is based on the ratio of PCA3 mRNA to PSA mRNA.
Data Bridge Market Research analyses that the prostate cancer antigen 3 (PCA3) test market which was USD 3.2 billion in 2021, is expected to reach USD 7.64 billion by 2029, at a CAGR of 11.50% during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Prostate Cancer Antigen 3 (PCA3) Test Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type of Test (Instruments, Kits and Reagent and Consumables), Test Type (Molecular, Serology), Technology (RT-PCR, ELISA Test, Micro-neutralization Assays), End Use (Hospitals, Clinics, Public Health Labs, Private or Commercial Labs, Physician Labs, Research Institutes, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
MDxHealth (Belgium), Myriad Genetics, Inc. (U.S.), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens, OPKO Health, Inc. (U.S.), Genomic Health (U.S.), BD (U.S.), Agilent Technologies, Inc. (U.S.) and Danaher (U.S.)
|
|
Market Opportunities
|
|
Market Definition
The prostate cancer antigen 3 gene (PCA3) test is used to assess your risk of developing prostate cancer. It is not used to make a diagnosis of prostate cancer. It is primarily used to determine whether your elevated prostate-specific antigen (PSA) levels are the result of prostate cancer. Prostate cancer is a type of cancer that develops in the prostate gland of men and is increasing at a significant rate each year. This cancer is commonly found in the elderly population, and it can have serious consequences such as blood in the sperm, bone pain, and erectile dysfunction, among others. As a result, early detection is required to avoid it at an early stage.
Global Prostate Cancer Antigen 3 (PCA3) Test Market Dynamics
Drivers
- Surging demand for early and precise diagnosis of prostate cancer
An increase in PSA levels raises the risk of prostate cancer. PSA concentrations in the blood are measured in nanograms per millilitre (ng/mL). There is no clear cut-off point for determining whether a man has prostate cancer or not. Many doctors use a PSA cut-off of 4 ng/mL or higher when determining whether a man requires further testing, while others may be starting at a lower level, such as 2.5 or 3. As a result, measuring PSA levels in a man's blood can help detect prostate cancer early. These are the certain factors which propel the growth of the market.
- Increasing demand for positron emission tomography
Positron emission tomography is increasingly being used as a diagnostic tool because it is more accurate than other diagnostic techniques. The accuracy of diagnosis has a direct impact on decision-making and treatment monitoring processes. Increasing demand for these diagnostic procedures is expected to drive the growth of the prostate cancer antigen 3 (PCA3) test market during the forecast period.
Opportunities
- Government initiatives will improve the growth rate
Increasing government initiatives for technological advancement to improve diagnosis, as well as an increase in the number of new entrants to invest in the market, are expected to drive market growth. Gregor Diagnostics, for example, recently invested USD 900000 to support its effort to develop home screening tests. Furthermore, the increasing demand for early detection and a better diagnostic system is expected to drive market growth.
Restraints/Challenges
- High cost of prostate cancer treatment will restrain the growth
High cost of prostate cancer nuclear medicine diagnostics and the low adoption rate in emerging and underdeveloped countries will obstruct the market's growth rate. There are health risks, because radiation is a side effect of nuclear medicine, prolonged exposure to it can cause health problems. This is especially true for infants, toddlers, elderly and pregnant women.
This prostate cancer antigen 3 (PCA3) test market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prostate cancer antigen 3 (PCA3) test market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent developments
- In April 2021, Coractive announced an investment of more than USD 24 million in the construction of a cutting-edge fibre optic production facility in Quebec City, Canada.
- In February 2021, Scientific Bioprocessing launched its Intelligent, Dynamic (ID) Fiber Optic Kit. The kit is a pH and dissolved oxygen sensing solution in one that provides real-time, non-invasive, and highly adaptable data from the smallest cell culture systems. It is the first cell monitoring product capable of sensing culture conditions within organ-on-a-chip systems in a reliable manner; it also provides bioprocessing engineers with novel cell culture sensing opportunities.
- In April 2022, Honeywell announced the addition of a blue-hued fibre to its Spectra Medical Grade (MG) Biofiber portfolio, providing a strong visual aid to distinguish between multiple suture sets in complex surgeries. This allows healthcare professionals to operate more accurately by creating clear colour contrast, which can lead to increased patient safety and comfort.
Global Prostate Cancer Antigen 3 (PCA3) Test Market Scope
The prostate cancer antigen 3 (PCA3) test market is segmented on the basis of type of test, technology, end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type of Test
- Instruments
- Kits and Reagent
- Consumables
- Molecular
- Serology
Technology
- RT-PCR
- ELISA Test
- Micro-neutralization Assays
End Use
- Hospitals
- Clinics
- Public Health Labs
- Private or Commercial Labs
- Physician Labs
- Research Institutes
- Others
Prostate Cancer Antigen 3 (PCA3) Test Market Regional Analysis/Insights
The prostate cancer antigen 3 (PCA3) test market is analysed and market size insights and trends are provided by country, type of test, technology, end use as referenced above.
The countries covered in the prostate cancer antigen 3 (PCA3) test market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the prostate cancer antigen 3 (PCA3) Test market due to the increasing prevalence of prostate cancer, increasing government initiative to spread awareness about early diagnosis, rising geriatric population are the factors driving the market growth in the region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to increasing health insurance schemes, rising geriatric population, government initiatives to develop healthcare infrastructure. Moreover, the changing lifestyle is also a factor behind increasing the rate number of patients.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The prostate cancer antigen 3 (PCA3) test market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for prostate cancer antigen 3 (PCA3) Test market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the prostate cancer antigen 3 (PCA3) Test market. The data is available for historic period 2010-2020.
Competitive Landscape and Prostate Cancer Antigen 3 (PCA3) Test Market Share Analysis
The prostate cancer antigen 3 (PCA3) test market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to prostate cancer antigen 3 (PCA3) Test market.
Some of the major players operating in the prostate cancer antigen 3 (PCA3) Test market are:
- MDxHealth (Belgium)
- Myriad Genetics, Inc. (U.S.)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Siemens (Germany)
- OPKO Health, Inc. (U.S.)
- Genomic Health (U.S.)
- BD (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Danaher (U.S.)
SKU-